• AMRN

Earnings call: Amarin reports Q3 revenue dip amid U.S. generic competition

Amarin Corporation reported Q3 2024 revenue decline due to generic competition, yet maintains a strong market position and focuses on global expansion of VASCEPA/VAZKEPA.